Holen Sie sich die Stockscreener-App
19.40
1.78%
0.34
Handel nachbörslich:
19.31
-0.09
-0.46%
Schlusskurs vom Vortag:
$19.06
Offen:
$18.64
24-Stunden-Volumen:
1.01M
Relative Volume:
0.35
Marktkapitalisierung:
$896.31M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-5.2861
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
+2.37%
1M Leistung:
+49.00%
6M Leistung:
+76.20%
1J Leistung:
+22.63%
1-Tages-Spanne:
$18.48
$19.58
1-Wochen-Bereich:
$18.37
$19.74
52-Wochen-Spanne:
$3.42
$19.74
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Vergleichen Sie URGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
19.40 | 880.60M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
What markets is FTAIN expanding into Is UroGen Pharma Ltd. stock a good long term investment optionMaximize gains with timely market signals - jammulinksnews.com
What catalysts could drive UroGen Pharma Ltd. stock higher in 2025Build wealth steadily with proven investment techniques - jammulinksnews.com
Should I hold or sell UroGen Pharma Ltd. stock in 2025Financial News Forecasts For Smart Trading - jammulinksnews.com
How does UroGen Pharma Ltd. compare to its industry peersRetirement Planning Alerts That Work - jammulinksnews.com
Is UroGen Pharma Ltd. stock overvalued or undervaluedBreakout Stocks Strategy With Low Risk - jammulinksnews.com
What is UroGen Pharma Ltd. company’s growth strategyStock Strategy Recommendation For Every Investor - jammulinksnews.com
What markets is UroGen Pharma Ltd. expanding into Is CPRX stock a good long term investment optionExpert Picks Forecasts Backed By Experts - jammulinksnews.com
UroGen Pharma Ltd. Could See a Relief Rally From SupportWatchlist for Low Risk High Return Stocks Updated - metal.it
UroGen Pharma Executives Sell Shares After Achieving Corporate Milestone - TradingView
Published on: 2025-07-30 03:03:07 - beatles.ru
What makes UroGen Pharma Ltd. stock price move sharplyLow Drawdown Real Time Trading Tips Shared - metal.it
Forecasting UroGen Pharma Ltd. price range with options dataReversal Alert Based on RSI Indicator Confirmed - metal.it
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 | URGN Stock News - GuruFocus
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 - GlobeNewswire
UroGen Pharma Q2 2025 Earnings: How to Access Live Results and Investor Call August 7 - Stock Titan
UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology - Insider Monkey
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
What institutional investors are buying UroGen Pharma Ltd. stockSmart Portfolio Growth Plan That Work - jammulinksnews.com
UroGen Pharma Ltd. Tests 50 Day MA After Sharp DeclineProfit Focused Stock Screener Results Released - metal.it
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Re - GuruFocus
UroGen Pharma Announces Publication of Phase 3b Study on At-Home Administration of ZUSDURI™ for Bladder Cancer Treatment - Quiver Quantitative
UroGen’s bladder cancer treatment shows promise for home administration - Investing.com
UroGen’s bladder cancer treatment shows promise for home administration By Investing.com - Investing.com Nigeria
UroGen Announces Publication of Phase 3b Study Results - GlobeNewswire
Revolutionary Home Treatment for Bladder Cancer Achieves 75% Response Rate in Clinical Trial - Stock Titan
Is UroGen Pharma Ltd. a growth stock or a value stockCapitalize on market momentum for maximum gains - jammulinksnews.com
UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025URGN - Finansavisen
How does UroGen Pharma Ltd. generate profit in a changing economyDiscover high-growth stocks for your portfolio - jammulinksnews.com
How strong is UroGen Pharma Ltd. company’s balance sheetAchieve consistent profits with expert strategies - jammulinksnews.com
What is the risk reward ratio of investing in UroGen Pharma Ltd. stockFree Technical Analysis Support - jammulinksnews.com
What are analysts’ price targets for UroGen Pharma Ltd. in the next 12 monthsBuild a diversified portfolio for steady growth - jammulinksnews.com
Why UroGen Pharma Ltd. stock attracts strong analyst attentionChart Based Entries - metal.it
How UroGen Pharma Ltd. stock performs during market volatilityTechnical Breakout List - metal.it
Is UroGen Pharma Ltd. a good long term investmentSuperior trading gains - PrintWeekIndia
UroGen Pharma Ltd. Stock Analysis and ForecastExponential wealth increase - PrintWeekIndia
Urogen Pharma Ltd. shares fall 1.90% after-hours following Tyra Biosciences' special call on Achondroplasia. - AInvest
What analysts say about UroGen Pharma Ltd. stockFree Wealth Planning Blueprint - PrintWeekIndia
What drives UroGen Pharma Ltd. stock priceFree Advanced Stock Screener Access - PrintWeekIndia
UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future - Yahoo Finance
UroGen’s revenue set to double by 2026 on bladder cancer drug rollout - S&P Global
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):